Biopharmx Corp. (NYSEMKT: BPMX)’s Phase 2a study of acne drug candidate BPX-01 turned positive results and the company is excited to continue with the development of the drug. BPX-01 will now enter Phase 2b study after exiting Phase 2a trial with encouraging outcome.
Biopharmx Corp. (NYSEMKT: BPMX)’s BPX-01 is a topical gel that contains minocycline and it is targeted at P. acnes.
The Phase 2a study
The Phase 2a study of BPX-01 enrolled 24 subjects, with 17 using BPX-01 once daily and 7 being in the control arm of the study. After four weeks of study, the subjects who used BPX-01 registered more than 90% reduction in their acne compared to the control group.
Biopharmx said that no adverse effects were noted in the subjects that received BPX-01 during the study. The company further said that traces of minocycline were not detected in the blood of the subjects who used BPX-01.
The results obtained in the Phase 2a study of BPX-01 were comparable to those reported in a study carried out in 1996 where oral minocycline. The 1996 study ended up citing oral minocycline as the most effective in fighting acne. But the problem with oral minocycline is that in enters the bloodstream of patients, thus causing unwanted side effects.
However, Biopharmx’s BPX-01, which is applied topically, is able to achieve the level of success of oral minocycline without getting into the bloodstream of users.
Phase 2b study – Biopharmx Corp. (NYSEMKT: BPMX)
Biopharmx Corp. (NYSEMKT: BPMX) intends to use a Phase 2b study of BPX-01 to confirm the results obtained in the Phase 2a trial. The management is optimistic that the next stage of BPX-01 trial will be successful as well.
It is estimated that acne affects close to 50 million Americans. According to American Academy of Dermatology, acne is the most common skin condition troubling people in the U.S. As such, in the U.S. alone the market for acne treatment is cited at $10 billion and Biopharmx Corp. (NYSEMKT: BPMX) is eying that market with BPX-01.